NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
Priority Review
APADAZ (benzhydrocodone and acetaminophen) by Zevra Therapeutics is hydrocodone. First approved in 2018.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APADAZ is an oral tablet combining benzhydrocodone (a mu-opioid agonist) and acetaminophen for pain relief. Hydrocodone provides potent analgesia through central opioid receptor activation with no ceiling effect, while acetaminophen provides complementary non-opioid analgesia. The combination is indicated for moderate to severe pain management in patients requiring opioid therapy.
Peak4.7 years to LOE
Product is at peak market penetration with 9 linked career positions; stable revenue phase supports established commercial teams.
Mechanism of Action
hydrocodone. Hydrocodone Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Worked on APADAZ at Zevra Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.